Anuncio • 14h
Ilika plc has completed a Follow-on Equity Offering in the amount of £4.555999 million. Ilika plc has completed a Follow-on Equity Offering in the amount of £4.555999 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 16,199,996
Price\Range: £0.28
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 71,429
Price\Range: £0.28
Transaction Features: Subsequent Direct Listing New Risk • Apr 21
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 5.6% per year for the foreseeable future. Revenue is less than US$1m (UK£665k revenue, or US$896k). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£7.3m net loss next year). Share price has been volatile over the past 3 months (8.5% average weekly change). Market cap is less than US$100m (UK£60.6m market cap, or US$81.7m). Anuncio • Mar 19
Ilika plc Announces Positive Feedback on Safety Testing of Goliath Cells by UK Defence Agency Ilika plc announced it has received positive feedback from a UK defence agency on safety tests of its batteries under battlefield conditions, highlighting the potential of the technology for use in high-risk, mission-critical environments where safety is paramount. In December 2025, Ilika delivered prototypes to customers across multiple industries, including an agency which advises the UK Ministry of Defence. The prototypes were subjected to firing range tests, which showed that: A Goliath 10Ah cell could survive a single shot before a thermal event was triggered by a second one; Low state-of-charge 10Ah Goliath cells did not show a thermal event; A Goliath cell showed a delayed reaction before entering thermal runaway; A Goliath cell reached a lower thermal runaway temperature than conventional Nickel Cobalt Aluminium ("NCA") lithium-ion cells; Despite Goliath 10Ah cells storing 3x the energy of conventional NCA cells being tested under equivalent conditions in the same trial, the Goliath cells had a similar thermal response. This independent validation follows the delivery of Goliath prototypes to multiple customers in December 2025 and supports Ilika's ongoing engagement with partners evaluating safety-critical applications. Under certain abuse conditions, conventional lithium-ion batteries can enter a state of thermal runaway, which is a chain reaction in which the battery temperature rises uncontrollably, leading to a fire or explosion. Major Estimate Revision • Jan 29
Consensus revenue estimates decrease by 46% The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast fell from UK£2.80m to UK£1.50m. EPS estimate unchanged from -UK£0.038 per share at last update. Electrical industry in the United Kingdom expected to see average net income growth of 22% next year. Consensus price target of UK£1.30 unchanged from last update. Share price fell 14% to UK£0.32 over the past week. New Risk • Jan 23
New major risk - Revenue size The company makes less than US$1m in revenue. Total revenue: UK£665k (US$898k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 5.6% per year for the foreseeable future. Revenue is less than US$1m (UK£665k revenue, or US$898k). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£7.3m net loss next year). Market cap is less than US$100m (UK£67.0m market cap, or US$90.5m). Reported Earnings • Jan 23
First half 2026 earnings released: UK£0.02 loss per share (vs UK£0.013 loss in 1H 2025) First half 2026 results: UK£0.02 loss per share (further deteriorated from UK£0.013 loss in 1H 2025). Net loss: UK£3.66m (loss widened 65% from 1H 2025). Revenue is forecast to grow 60% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Electrical industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. New Risk • Jan 21
New major risk - Revenue and earnings growth Earnings have declined by 7.8% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 7.8% per year over the past 5 years. Minor Risks Revenue is less than US$5m (UK£1.1m revenue, or US$1.4m). Market cap is less than US$100m (UK£66.1m market cap, or US$88.6m). New Risk • Dec 11
New major risk - Revenue and earnings growth Earnings have declined by 7.8% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 7.8% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Revenue is less than US$5m (UK£1.1m revenue, or US$1.4m). Anuncio • Nov 20
Ilika plc to Report First Half, 2026 Results on Jan 22, 2026 Ilika plc announced that they will report first half, 2026 results on Jan 22, 2026 Reported Earnings • Aug 29
Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2025 results: UK£0.037 loss per share (further deteriorated from UK£0.03 loss in FY 2024). Net loss: UK£5.90m (loss widened 23% from FY 2024). Revenue missed analyst estimates by 25%. Earnings per share (EPS) exceeded analyst estimates by 12%. Revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Electrical industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings. Anuncio • Aug 28
Ilika plc, Annual General Meeting, Sep 23, 2025 Ilika plc, Annual General Meeting, Sep 23, 2025. Location: the offices of eversheds sutherland llp, one wood street, london ec2v 7ws United Kingdom Reported Earnings • Jul 18
Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2025 results: UK£0.037 loss per share (further deteriorated from UK£0.03 loss in FY 2024). Net loss: UK£5.90m (loss widened 23% from FY 2024). Revenue missed analyst estimates by 25%. Earnings per share (EPS) exceeded analyst estimates by 12%. Revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Electrical industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. New Risk • Jul 17
New major risk - Revenue and earnings growth Earnings have declined by 10% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 10% per year over the past 5 years. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (UK£4.3m net loss in 2 years). Share price has been volatile over the past 3 months (7.6% average weekly change). Revenue is less than US$5m (UK£1.7m revenue, or US$2.3m). Anuncio • Jul 16
Ilika plc Announces Award of Government Grant Funding Ilika announced it is receiving further grant support to manufacture the first Goliath A-Sample batteries for automotive applications. This support is being provided from the newly launched Demonstrate fund, facilitated by the Advanced Propulsion Centre UK (APC), in a 12-month, £3 million collaboration programme, of which Ilika will receive £1.25 million in grant funding. The programme which will commence on 1 August 2025 will see Ilika partner with HSSMI, a UK based manufacturing consultancy and utilise the electrode production lines at the UK Battery Industrialisation Centre ("UKBIC"). This project, codenamed PRIMED builds upon the developments in the Faraday Battery Challenge, now renamed Battery Innovation Programme, project HISTORY, where Ilika developed a prototype 50Ah SSB, and the APC's Automotive Transformation Fund (ATF) programme SiSTEM, which designed and built an SSB assembly line and undertook production trials of Ilika's electrodes on the giga-scale line at UKBIC. In PRIMED, Ilika will build and test its P2 SSB cells and take them through an industrialisation process to deliver a 50Ah A-Sample. HSSMI will produce a Production Scale Model and Business Case Review to support industrialisation to a gigafactory level. Anuncio • Jun 11
Ilika plc to Report Fiscal Year 2025 Results on Jul 17, 2025 Ilika plc announced that they will report fiscal year 2025 results on Jul 17, 2025 Anuncio • May 29
Ilika plc has completed a Follow-on Equity Offering in the amount of £0.9 million. Ilika plc has completed a Follow-on Equity Offering in the amount of £0.9 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 2,727,273
Price\Range: £0.33
Transaction Features: Regulation S Anuncio • May 23
Ilika plc has filed a Follow-on Equity Offering in the amount of £0.5 million. Ilika plc has filed a Follow-on Equity Offering in the amount of £0.5 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,515,151
Price\Range: £0.33 Price Target Changed • May 22
Price target increased by 25% to UK£1.02 Up from UK£0.81, the current price target is an average from 2 analysts. New target price is 184% above last closing price of UK£0.36. Stock is up 28% over the past year. The company is forecast to post a net loss per share of UK£0.041 next year compared to a net loss per share of UK£0.03 last year. Anuncio • May 22
Ilika plc has filed a Follow-on Equity Offering in the amount of £3 million. Ilika plc has filed a Follow-on Equity Offering in the amount of £3 million.
Security Name: Ordinary Share
Security Type: Common Stock
Securities Offered: 9,009,090
Price\Range: £0.33
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 81,819
Price\Range: £0.33
Transaction Features: Regulation S; Subsequent Direct Listing Anuncio • Apr 15
Ilika plc Announces Goliath Battery Achieves Scale-Up Milestone Ilika plc confirmed superior performance of its Goliath batteries manufactured via an industrially scaled process at The UK Battery Industrialisation Centre. This further underpins confidence that the battery is on track on its route to market, reducing costs, increasing range and reducing charging time of electric vehicles. This follows Ilika's 5 February 2025 announcement reporting large-scale preparation of the Goliath electrolyte and successful coating of its proprietary composite electrolyte-electrode. Ilika has used these materials to build a batch of solid state 10Ah prototype cells. After analysis of the performance of these cells, Ilika can verify that the scaled manufacturing process at UKBIC resulted in a higher manufacturing yield and has delivered cells superior in performance to those made with similar starting materials on Ilika's pilot line. This confirms that the tolerances of industrial equipment will unlock further improvements to Goliath SSB technology. The increase in manufacturing yield resulted from enhanced handling robustness after coating and fewer defects from the drying process. The superior performance was measured as higher battery capacity under rapid charging protocols. Ilika announced in October 2023 receipt of grant support from the Automotive Transformation Fund ('ATF') through an 18-month, £2.7 million collaboration programme, codenamed Project SiSTEM, to scale up Ilika's Goliath solid-state battery production capability. Via the programme, Ilika partnered with Mpac Group plc ('Mpac') global supplier of packaging and assembly automation, UKBIC and Agratas, Tata Group's global battery business. Through this collaboration, UKBIC and Ilika have carried out physical trials to demonstrate preparation and roll-to-roll coating of its proprietary solid state materials. The planned trials are now complete and the cell test data announced provide evidence that Ilika's approach to large format solid-state battery manufacture can be carried out with the types of mixing and coating equipment widely used in existing gigafactories. In addition, the trials show that the quality of product made on large scale equipment actually improves with scale. Project SiSTEM has now successfully completed, with the associated delivery of the 1.5MWh solid-state battery assembly line from Mpac planned for second half Current Year 2025. The assembly line will be capable of producing Ilika's Goliath prototype large-format pouch cells to automotive original equipment manufacturers and Tier 1 suppliers, in line with planned delivery timeline. Anuncio • Mar 06
Ilika plc Announces Goliath Development Progress Ilika announced it has successfully prototyped a 50Ah Goliath electric vehicle (EV) battery, which is a key targeted outcome of the Faraday Battery Challenge HISTORY programme. The 50Ah prototype is the capacity of battery Ilika will now optimise for its minimum viable product for EVs. The battery is expected to reduce costs, increase the range of EVs and reduce their charging time. This successful prototype build follows the recently announced demonstration of manufacturing in a giga-scale factory setting, using industry standard equipment at the UK Battery Industrialisation Centre, marking the latest step towards commercialisation. It builds on the progress made in 2024 which included the start of commercial testing, shipping of the first batch of prototype Goliath batteries to customers, and the release of validated safety data. Ilika will now undertake further optimisation based on the initial test results, before commencing a build and test programme in H2 CY 2025. The Company is targeting an initial release of batteries of this capacity for partner evaluation from the end of CY 2025. New Risk • Feb 05
New major risk - Revenue and earnings growth Earnings have declined by 13% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 13% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Revenue is less than US$5m (UK£1.7m revenue, or US$2.2m). Market cap is less than US$100m (UK£45.2m market cap, or US$56.6m). Reported Earnings • Jan 22
First half 2025 earnings released: UK£0.013 loss per share (vs UK£0.016 loss in 1H 2024) First half 2025 results: UK£0.013 loss per share (improved from UK£0.016 loss in 1H 2024). Net loss: UK£2.22m (loss narrowed 14% from 1H 2024). Revenue is forecast to grow 38% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Electrical industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 43% per year, which means it is significantly lagging earnings. Anuncio • Jan 09
Ilika plc Announces the Production of Stereax Batteries for Process Qualification Now Commence Ilika announced that the production of Stereax batteries for process qualification has now commenced. In July 2024, Ilika confirmed that installation of its key equipment had been substantially completed in Cirtec Medical's facility in Lowell, MA, USA. Ilika can now confirm its equipment has been commissioned and successfully passed its User Acceptance Tests (UATs). These production tools include layer deposition machines as well as alignment and patterning machines. This final stage in the commissioning of Stereax new manufacturing facilities means that both Cirtec and Ilika are now satisfied that the equipment meets its requirement for the start of production transfer. To support equipment commissioning, since June 2024, Ilika has delivered a series of batches of cathode-coated wafers to Cirtec, for further processing and verification of subsequent process steps. Process qualification has the aim of refining and tuning the process equipment to achieve specified product performance in preparation for the start of product manufacturing. Ilika currently retains and will operate part of the production equipment in the UK, including that for cathode deposition and cell formation and testing. In August 2023, Ilika and Cirtec Medical announced that they had concluded contractual negotiations by signing a ten-year manufacturing licence to produce the Stereax range of mm-scale batteries at Cirtec's facility in Lowell. This partnership will reinforce Cirtec's ongoing activities in system level miniaturisation for the medical device industry, whilst Ilika will focus on advanced technology development and IP licensing in support of Cirtec's manufacturing and commercialisation activities. Anuncio • Nov 20
Ilika plc Announces Goliath D6 Milestone Reaches Ramping Up Ev Battery Capacity Ilika announced that it has successfully reached its D6 milestone by testing 10Ah cells in its Goliath solid state batteries for electric vehicles. The systematic testing to industry standards demonstrates the increased capacity of its cells as it systematically moves along its development roadmap for customers. Building and successfully testing these larger 10Ah cells follows on from the announcement last month on 3 October 2024 of compelling safety data from the testing of its Goliath D5 prototypes. Ilika is now progressing with development towards a D7 design freeze, which it expects to achieve in first quarter 2025. The D7 design freeze will form the basis of a release of 10Ah prototype cells to customers, called the P1.5 prototypes, which will be an upgrade on the 2Ah P1 prototypes released in July 2024. This intermediate P1.5 prototype will address automotive OEM requests for a further proof-point of the technology, as Goliath scales up beyond the capacity of cells released by some competitors. The timing of the P1.5 release will be driven by completion of testing of a batch of batteries based on the D7 design, by second quarter 2025. The 2025 development roadmap will then extend to D8 design freeze, which is also expected in first quarter 2025, and then to the crucial Minimum Viable Product ("MVP") stage, targeted for the end of 2025. Ilika's Goliath MVP, or 50Ah P2 prototypes, will underpin revenue generating licensing opportunities. The modelling of a Goliath-based battery pack for EVs is underway by UK company Balance Batteries, that capitalises on the superior safety, high energy density and fast charging features of the Goliath cells. Early results show that the weight of the battery pack can be reduced materially by up to 100 kg on the basis of Goliath's benefits, compared to a current SUV lithium-ion model of the same energy. This reduction in weight translates into increased driving range on the same level of battery charge and reduced vehicle cost. Anuncio • Nov 15
Ilika plc to Report First Half, 2025 Results on Jan 21, 2025 Ilika plc announced that they will report first half, 2025 results on Jan 21, 2025 Anuncio • Oct 03
Ilika plc Completes Testing of Its Goliath D5 Prototypes Ilika announces it has completed testing of its Goliath D5 prototypes, thereby further confirming the safety characteristics of Ilika's batteries. The testing reconfirmed the benefits of Goliath relative to lithium-ion equivalent across a number of key variables - reinforcing the fact that Ilika's cells have the potential to provide electric vehicles (EV) with lighter, safer, cheaper batteries with longer ranges and faster charging capabilities. The D5 prototype is designed to build on the characteristics of the D4 data point achieved in 2023. This was achieved by optimising the cell architecture to increase Goliath's unique safety value proposition without compromising cell energy density. The key findings from the testing programme provide further validation along the development curve to D8 and MVP samples during calendar year 2025: Exceptional results from the nail penetration test carried out by University College London as part of the Faraday Institution funded Safebatt Industrial Sprint programme. The results classify puncturing the D5 prototypes as a EUCAR 3 hazard event, with no leakage, no venting, no fire or flame, no rupture and no explosion. In contrast, puncturing the benchmark lithium-ion battery resulted in a higher EUCAR 6 event, i.e. a rupture accompanied by flying parts of the active mass, fire and flame. Components confirmed to be non-flammable by DEKRA, the world's largest independent, non-listed expert organisation in testing, certification and inspection. Temperatures during failure approximately 300°C lower than comparable Li-ion cells shown in Accelerated Rate Calorimetry testing carried out as part the Industrial Sprint, by the University of Oxford. Improved capacity at higher discharge rates. o D5 prototypes can be discharged at twice the rate of P1 prototypes without impacting their capacity. Improved safety performance of Goliath batteries relative to conventional lithium ion means that EV designers can reduce the mechanical protection and reinforcement that would otherwise be required to protect the battery pack. In turn, this enables lighter and less expensive EV designs that have a longer range for the same amount of energy. The D5 data point makes this improved safety performance clear. Anuncio • Sep 05
Ilika plc Announces Goliath Safety Test Results Ilika plc announced that safety tests undertaken by independent expert assessors have demonstrated the superior safety of Goliath solid state cell battery prototypes relative to lithium-ion equivalent batteries. University College London carried out the nail penetration test, a standard battery safety assessment, on Ilika's Goliath P1 prototype cells. This destructive test creates an internal electrical short-circuit inside a cell by piercing the cell with a metal nail. The test simulates a catastrophic incident that would typically cause energy-dense lithium-ion cells with lithium nickel manganese cobalt oxide ("NMC") cathode chemistry (, to dangerously swell, rupture, explode, and catch fire in a process known as thermal runaway, often leading to temperatures above 600°C. Goliath P1 cells also use high-energy NMC cathode chemistry, however in the nail penetration tests the P1 cells neither exploded nor caught fire, with external temperatures remaining below 80°C. With electric vehicles ("EVs") expected to play a key role in the NetZero transition, solid state batteries are anticipated to provide a safer battery solution for next-generation EVs. It is expected that a combination of improved safety performance and high energy density will reduce the complexity of battery packs. The reduction of parasitic packaging is, in turn, expected to lead to lighter and safer vehicles with longer driving range. Testing was carried out as part of a short collaborative study, in association with the Faraday Institution SafeBatt project,which aims to develop an improved understanding of safety in next generation battery technologies. The study involves Ilika alongside researchers from the University of Oxford and University College London. The core Safebatt project explores the science of battery safety and works closely with UK battery developers and manufacturers like Ilika to inform industrial design and deployment. Anuncio • Aug 29
Ilika plc, Annual General Meeting, Sep 24, 2024 Ilika plc, Annual General Meeting, Sep 24, 2024. Location: the offices of eversheds sutherlands llp, one wood street, ec2v 7ws, london United Kingdom New Risk • Jul 17
New major risk - Revenue and earnings growth Earnings have declined by 21% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 21% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (5.3% increase in shares outstanding). Revenue is less than US$5m (UK£2.1m revenue, or US$2.7m). Market cap is less than US$100m (UK£45.7m market cap, or US$59.5m). Reported Earnings • Jul 12
Full year 2024 earnings: EPS exceeds analyst expectations Full year 2024 results: UK£0.03 loss per share (improved from UK£0.046 loss in FY 2023). Net loss: UK£4.81m (loss narrowed 34% from FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 5.3%. Revenue is forecast to grow 54% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Electrical industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 43% per year, which means it is performing significantly worse than earnings. New Risk • Jun 03
New major risk - Revenue and earnings growth Earnings have declined by 26% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 26% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (4.2% increase in shares outstanding). Revenue is less than US$5m (UK£1.8m revenue, or US$2.3m). Market cap is less than US$100m (UK£45.4m market cap, or US$57.7m). New Risk • May 19
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 4.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (UK£5.0m net loss in 2 years). Shareholders have been diluted in the past year (4.2% increase in shares outstanding). Revenue is less than US$5m (UK£1.8m revenue, or US$2.3m). Market cap is less than US$100m (UK£46.2m market cap, or US$58.8m). Anuncio • May 17
Ilika plc to Report Fiscal Year 2024 Results on Jul 11, 2024 Ilika plc announced that they will report fiscal year 2024 results on Jul 11, 2024 Price Target Changed • May 12
Price target decreased by 26% to UK£0.65 Down from UK£0.88, the current price target is provided by 1 analyst. New target price is 124% above last closing price of UK£0.29. Stock is down 40% over the past year. The company is forecast to post a net loss per share of UK£0.037 next year compared to a net loss per share of UK£0.046 last year. New Risk • Apr 26
New major risk - Revenue and earnings growth Earnings have declined by 26% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 26% per year over the past 5 years. Minor Risks Revenue is less than US$5m (UK£1.8m revenue, or US$2.3m). Market cap is less than US$100m (UK£48.5m market cap, or US$60.6m). Price Target Changed • Apr 24
Price target decreased by 11% to UK£0.82 Down from UK£0.93, the current price target is an average from 2 analysts. New target price is 189% above last closing price of UK£0.28. Stock is down 47% over the past year. The company posted a net loss per share of UK£0.046 last year. Anuncio • Apr 23
Ilika plc Provides Revenue Guidance for the Year Ended 30 April 2024 Ilika plc announced that unaudited trading for the year ended 30 April 2024 has been in line with current market expectations and the Company expects to generate revenue of approximately £2.0 million (FY 2023: £0.8 million). Reported Earnings • Jan 24
First half 2024 earnings released: UK£0.016 loss per share (vs UK£0.026 loss in 1H 2023) First half 2024 results: UK£0.016 loss per share (improved from UK£0.026 loss in 1H 2023). Net loss: UK£2.59m (loss narrowed 37% from 1H 2023). Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Electrical industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has fallen by 48% per year, which means it is performing significantly worse than earnings. Major Estimate Revision • Nov 26
Consensus revenue estimates increase by 54% The consensus outlook for revenues in fiscal year 2024 has improved. 2024 revenue forecast increased from UK£1.30m to UK£2.00m. Forecast losses expected to reduce from -UK£0.039 to -UK£0.036 per share. Electrical industry in the United Kingdom expected to see average net income growth of 19% next year. Consensus price target of UK£0.93 unchanged from last update. Share price rose 49% to UK£0.44 over the past week. Anuncio • Nov 24
Ilika plc to Report First Half, 2024 Results on Jan 23, 2024 Ilika plc announced that they will report first half, 2024 results on Jan 23, 2024 New Risk • Nov 24
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 28% per year over the past 5 years. Revenue is less than US$1m (UK£702k revenue, or US$880k). Minor Risk Market cap is less than US$100m (UK£68.3m market cap, or US$85.6m). Reported Earnings • Aug 20
Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2023 results: UK£0.046 loss per share. Net loss: UK£7.30m (loss widened 2.3% from FY 2022). Revenue missed analyst estimates by 22%. Earnings per share (EPS) exceeded analyst estimates by 11%. Revenue is forecast to grow 49% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Electrical industry in the United Kingdom. Anuncio • Aug 18
Ilika plc, Annual General Meeting, Sep 20, 2023 Ilika plc, Annual General Meeting, Sep 20, 2023, at 13:00 Coordinated Universal Time. Location: At the offices of Eversheds Sutherlands LLP One Wood Street, London EC2V 7WS London United Kingdom Reported Earnings • Jul 14
Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2023 results: UK£0.046 loss per share. Net loss: UK£7.30m (loss widened 2.3% from FY 2022). Revenue missed analyst estimates by 22%. Earnings per share (EPS) exceeded analyst estimates by 11%. Revenue is forecast to grow 46% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Electrical industry in the United Kingdom. Anuncio • May 23
Ilika plc to Report Fiscal Year 2023 Results on Jul 13, 2023 Ilika plc announced that they will report fiscal year 2023 results on Jul 13, 2023 Anuncio • May 22
Ilika plc Provides Revenue Guidance for the Year Ended 30 April 2023 Ilika plc announced that unaudited trading for the year ended 30 April 2023 has been in line with management expectations. The Company expects to announce revenues of approximately £0.8 million (2022: £0.5 million). Anuncio • May 11
Ilika plc Announces First Customer Shipments of Stereax M300 Stacked Batteries Ilika announced it has made a number of first customer shipments of stacked Stereax® M300 batteries from its UK manufacturing facility. Further to its announcement of 11 April 2023, these shipments are the first of a series of planned deliveries of Stereax M300 batteries to customers including CubeWorks, the developer of millimeter-scale smart sensing solutions for IoT, and Lura Health, a leading developer of wearable intraoral biosensors for salivary diagnostics. Stereax batteries can be configured such that they can be stacked, which provides customers with the flexibility to adapt the battery capacity for their application. The small form factor of M300 batteries is of particular interest to Ilika's customers due to their compact, high-density and high-power characteristics. CubeWorks is designing CubiSensTM, a next generation sensing platform, aiming to transform biopharma cold chain logistics, security control, asset protection and environment monitoring. Lura Health has developed the world's first salivary diagnostic, wearable sensor, first embedded in traditional orthodontic appliances including retainers, bands, and brackets, and eventually in prosthodontic appliances including dentures, implants, and bridges. Worn in the mouth continually throughout the day, it continually measures analytes in saliva, and provides real time streams of health data by Bluetooth Low Energy to a smartphone. Cirtec Update Ilika and Cirtec Medical LLC ('Cirtec'), a strategic outsourcing partner of complex medical devices including minimally invasive and active implantable devices, are continuing to finalise the terms of their intended partnership. Price Target Changed • Mar 28
Price target increased by 20% to UK£0.87 Up from UK£0.72, the current price target is an average from 4 analysts. New target price is 141% above last closing price of UK£0.36. Stock is down 72% over the past year. The company is forecast to post a net loss per share of UK£0.056 next year compared to a net loss per share of UK£0.047 last year. Reported Earnings • Jan 20
First half 2023 earnings released: UK£0.03 loss per share (vs UK£0.022 loss in 1H 2022) First half 2023 results: UK£0.03 loss per share (further deteriorated from UK£0.022 loss in 1H 2022). Net loss: UK£4.08m (loss widened 25% from 1H 2022). Revenue is forecast to grow 63% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Electrical industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings. Major Estimate Revision • Nov 19
Consensus forecasts updated The consensus outlook for 2023 has been updated. 2023 revenue forecast fell from UK£970.0k to UK£630.0k. EPS estimate reaffirmed at -UK£0.05 per share. Electrical industry in the United Kingdom expected to see average net income growth of 18% next year. Consensus price target down from UK£1.37 to UK£0.89. Share price fell 35% to UK£0.32 over the past week. Price Target Changed • Nov 17
Price target decreased to UK£1.10 Down from UK£1.47, the current price target is an average from 4 analysts. New target price is 255% above last closing price of UK£0.31. Stock is down 78% over the past year. The company is forecast to post a net loss per share of UK£0.055 next year compared to a net loss per share of UK£0.047 last year. Anuncio • Nov 17
Ilika plc to Report First Half, 2023 Results on Jan 19, 2023 Ilika plc announced that they will report first half, 2023 results on Jan 19, 2023 Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. Independent Non-Executive Director Monika Biddulph was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Price Target Changed • Sep 12
Price target decreased to UK£1.37 Down from UK£1.49, the current price target is an average from 3 analysts. New target price is 81% above last closing price of UK£0.76. Stock is down 48% over the past year. The company is forecast to post a net loss per share of UK£0.051 next year compared to a net loss per share of UK£0.047 last year. Reported Earnings • Jul 14
Full year 2022 earnings: EPS exceeds analyst expectations Full year 2022 results: UK£0.047 loss per share (down from UK£0.025 loss in FY 2021). Net loss: UK£7.13m (loss widened 102% from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 4.5%. Over the next year, revenue is forecast to grow 81%, compared to a 90% growth forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings. Price Target Changed • Apr 27
Price target decreased to UK£2.53 Down from UK£2.78, the current price target is an average from 3 analysts. New target price is 141% above last closing price of UK£1.05. Stock is down 55% over the past year. The company is forecast to post a net loss per share of UK£0.054 next year compared to a net loss per share of UK£0.025 last year. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. Independent Non-Executive Director Monika Biddulph was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Recent Insider Transactions • Mar 23
Finance Director recently sold UK£120k worth of stock On the 21st of March, Stephen Boydell sold around 112k shares on-market at roughly UK£1.07 per share. This was the largest sale by an insider in the last 3 months. Stephen has been a seller over the last 12 months, reducing personal holdings by UK£122k. Board Change • Feb 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 1 highly experienced director. Independent Non-Executive Director Monika Biddulph was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • Jan 22
First half 2022 earnings: EPS and revenues exceed analyst expectations First half 2022 results: UK£0.022 loss per share (down from UK£0.012 loss in 1H 2021). Net loss: UK£3.27m (loss widened 101% from 1H 2021). Revenue exceeded analyst estimates by 61%. Earnings per share (EPS) also surpassed analyst estimates by 7.7%. Over the next year, revenue is forecast to grow 193%, compared to a 216% growth forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 73% per year, which means it is well ahead of earnings. Major Estimate Revision • Dec 15
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 revenue forecast fell from UK£900.0k to UK£750.0k. EPS estimate reaffirmed at -UK£0.05 per share. Electrical industry in the United Kingdom expected to see average net income growth of 12% next year. Consensus price target of UK£2.53 unchanged from last update. Share price fell 27% to UK£1.40 over the past week. Price Target Changed • Nov 19
Price target decreased to UK£2.53 Down from UK£2.90, the current price target is an average from 2 analysts. New target price is 80% above last closing price of UK£1.41. Stock is up 35% over the past year. The company is forecast to post a net loss per share of UK£0.054 next year compared to a net loss per share of UK£0.025 last year. Reported Earnings • Aug 20
Full year 2021 earnings released: UK£0.025 loss per share (vs UK£0.03 loss in FY 2020) Full year 2021 results: Net loss: UK£3.53m (loss widened 14% from FY 2020). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has increased by 86% per year, which means it is tracking significantly ahead of earnings growth. Major Estimate Revision • Aug 03
Consensus revenue estimates fall to UK£1.70m The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from UK£2.20m to UK£1.70m. Forecast losses increased from -UK£0.028 to -UK£0.043 per share. Electrical industry in the United Kingdom expected to see average net income growth of 9.9% next year. Consensus price target of UK£2.90 unchanged from last update. Share price fell 7.4% to UK£1.44 over the past week. Reported Earnings • Jul 07
Full year 2021 earnings released: UK£0.025 loss per share (vs UK£0.03 loss in FY 2020) Full year 2021 results: Net loss: UK£3.53m (loss widened 14% from FY 2020). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has increased by 112% per year, which means it is tracking significantly ahead of earnings growth. Is New 90 Day High Low • Feb 08
New 90-day high: UK£2.72 The company is up 189% from its price of UK£0.94 on 10 November 2020. The British market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Electrical industry, which is up 80% over the same period. Is New 90 Day High Low • Jan 23
New 90-day high: UK£2.55 The company is up 183% from its price of UK£0.90 on 23 October 2020. The British market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Electrical industry, which is up 56% over the same period. Reported Earnings • Jan 16
First half 2021 earnings released: UK£0.012 loss per share First half 2021 results: Net loss: UK£1.62m (loss widened 13% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 92% per year, which means it is tracking significantly ahead of earnings growth. Is New 90 Day High Low • Dec 23
New 90-day high: UK£1.11 The company is up 30% from its price of UK£0.85 on 23 September 2020. The British market is up 9.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Electrical industry, which is up 50% over the same period. Is New 90 Day High Low • Nov 16
New 90-day high: UK£1.01 The company is up 52% from its price of UK£0.67 on 18 August 2020. The British market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Electrical industry, which is up 29% over the same period. Anuncio • Jun 16
Ilika Announces Re-Opens Stereax® Pilot Line at University of Southampton Ilika provided an update on the Company's operational activities and in particular the re-opening of its Stereax® pilot line at the University of Southampton. In order to prioritise the safety of staff, their families and customers the company is continuing to comply with UK Government directives to avoid non-essential travel and to maximise home-working. Throughout the lockdown period, the Company's headquarters in Romsey, UK have remained open for those employees who need access to the company's Goliath large format cell development facilities. Through the implementation of risk assessments, enhanced cleaning and hygiene procedures and social distancing the company has maintained a safe working environment and are pleased to confirm that employees have not experienced any potentially COVID-19 related sickness since March.